U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07646106) titled 'THE-0504 in Patients With Solid Tumors' on June 03.
Brief Summary: Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with different types of solid tumors.
Study Start Date: Nov. 13, 2024
Study Type: INTERVENTIONAL
Condition:
Small Cell Lung Cancer (SCLC)
Colorectal Carcinoma (CRC)
Gastric Cancer (GC)
Triple -Negative Breast Cancer
Pancreas Adenocarcinoma
Intervention:
DRUG: THE-0504
THE-0504 will be administered intravenously according to the treatment regimen specified in the protocol.
Recruitment Status: RECR...